Japan is one of the most appealing markets for medical imaging and radiopharmaceuticals. The radiopharmaceuticals market is experiencing a rise in popularity because of increasing recognition amongst both individuals and medical professionals about its usages, adoption of brand-new technologies, and availability of radiopharmaceuticals. Therefore, growth of the radiopharmaceuticals industry in Japan is expected to remain constant during the forecast duration. Major players in the industry are increasing their focus on certain applications by conducting R&D tasks as well as introducing new products. The rising healthcare expenses are anticipated to have a positive impact on the Japan radiopharmaceuticals market growth.
The major driving factor for the expansion of the Japan radiopharmaceuticals market is the rising occurrence of cancer cells. The growing demand for radioisotope imaging techniques has been a significant element driving the market development. In addition, there is a considerable rise in financial investment in medical care sector, specifically in major cities as well as bigger urban locations, which has a positive impact on the radiopharmaceuticals market size.
The Japan radiopharmaceuticals market also faces specific restraints because of obstacles posed by the economic circumstances as well as changes in federal government guidelines. The federal government is imposing rigorous guidelines on the production, sale, as well as circulation of radiopharmaceuticals, which can interfere with the development of the marketplace. In addition, radiopharmaceuticals are costly, which restricts its demand as well as accessibility among patients in the country.
The government of Japan is focusing on enhancing the health care framework as well as is investing greatly in the advancement of brand-new technologies, which is expected to boost the demand for radiopharmaceuticals in the upcoming years. In addition, advancements in nuclear medicine imaging are expected to increase the need for radiopharmaceuticals in the country. The growth of novel radiopharmaceuticals, as well as research tasks focused on the advancement of new applications for existing items, are anticipated to create new market opportunities.
There is scope for significant expansion in the market for radiopharmaceuticals in the future due to the rising prevalence of cancer cells and also various other illness in Japan. The development of innovative radiopharmaceuticals with enhanced efficacy will likewise create several growth opportunities for key players operating in the market. In addition, the federal government initiatives to lower the price of radiopharmaceuticals and increase patient access to them is anticipated to boost the market expansion.
The government of Japan has imposed stringent laws on the manufacturing, sale, and circulation of radiopharmaceuticals. The nation's Pharmaceutical Affairs Law (PAL) is responsible for regulating the circulation and sale of radiopharmaceuticals.
The Japan radiopharmaceuticals market is segmented on the basis of radioisotope, type, application, and end user. On the basis of radioisotope, the market is divided into Technetium 99m, Fluorine 18, Iodine I, Gallium 68, and others. On the basis of application, the market is classified into cancer, cardiology, and others. On the basis of type, the market is divided into diagnostic and therapeutic. On the basis of end user, the market is classified into hospitals & clinics, medical imaging centers, and others.
The Japan radiopharmaceuticals market is anticipated to expand continuously during the forecast period, owing to the increasing focus on cancer cells care, technical advancements, and infrastructure growth in the country. Moreover, the increasing need for brand-new applications of radiopharmaceuticals is anticipated to drive the market growth in the future. In addition, rising recognition as well as acceptance of advanced imaging methods is expected to drive the market expansion. The government has launched several efforts to increase radiopharmaceuticals affordability and accessibility, which is projected to support the market growth.
One of the significant factors driving the market growth for radiopharmaceuticals is the rise in the prevalence of chronic diseases such as cancer, cardiovascular disease, and neurology. Radiopharmaceuticals are radioactive drugs that are used to detect and treat cancer cells. They are administered into the body and accumulate in cancerous tissues, allowing for the diagnosis and treatment of the disease.
Around 1.9 million new cancer cases were estimated to have been identified in the U.S. in 2022, according to American cancer Society. In addition, the National Cancer Institute reported that around 50% of all cancer patients are prescribed with radiation therapy at some point during their treatment.
The Japan radiopharmaceuticals market is expected to witness product advancements in the future. With breakthroughs in innovation and also an enhanced focus on medical care framework in the country, companies operating in the market are progressively investing in R&D in order to develop brand-new radiopharmaceuticals with improved efficacy and safety.
The major driving factor for the expansion of the Japan radiopharmaceuticals market is the rising occurrence of cancer cells. The growing demand for radioisotope imaging techniques has been a significant element driving the market development. In addition, there is a considerable rise in financial investment in medical care sector, specifically in major cities as well as bigger urban locations, which has a positive impact on the radiopharmaceuticals market size.
The Japan radiopharmaceuticals market also faces specific restraints because of obstacles posed by the economic circumstances as well as changes in federal government guidelines. The federal government is imposing rigorous guidelines on the production, sale, as well as circulation of radiopharmaceuticals, which can interfere with the development of the marketplace. In addition, radiopharmaceuticals are costly, which restricts its demand as well as accessibility among patients in the country.
The government of Japan is focusing on enhancing the health care framework as well as is investing greatly in the advancement of brand-new technologies, which is expected to boost the demand for radiopharmaceuticals in the upcoming years. In addition, advancements in nuclear medicine imaging are expected to increase the need for radiopharmaceuticals in the country. The growth of novel radiopharmaceuticals, as well as research tasks focused on the advancement of new applications for existing items, are anticipated to create new market opportunities.
There is scope for significant expansion in the market for radiopharmaceuticals in the future due to the rising prevalence of cancer cells and also various other illness in Japan. The development of innovative radiopharmaceuticals with enhanced efficacy will likewise create several growth opportunities for key players operating in the market. In addition, the federal government initiatives to lower the price of radiopharmaceuticals and increase patient access to them is anticipated to boost the market expansion.
The government of Japan has imposed stringent laws on the manufacturing, sale, and circulation of radiopharmaceuticals. The nation's Pharmaceutical Affairs Law (PAL) is responsible for regulating the circulation and sale of radiopharmaceuticals.
The Japan radiopharmaceuticals market is segmented on the basis of radioisotope, type, application, and end user. On the basis of radioisotope, the market is divided into Technetium 99m, Fluorine 18, Iodine I, Gallium 68, and others. On the basis of application, the market is classified into cancer, cardiology, and others. On the basis of type, the market is divided into diagnostic and therapeutic. On the basis of end user, the market is classified into hospitals & clinics, medical imaging centers, and others.
The Japan radiopharmaceuticals market is anticipated to expand continuously during the forecast period, owing to the increasing focus on cancer cells care, technical advancements, and infrastructure growth in the country. Moreover, the increasing need for brand-new applications of radiopharmaceuticals is anticipated to drive the market growth in the future. In addition, rising recognition as well as acceptance of advanced imaging methods is expected to drive the market expansion. The government has launched several efforts to increase radiopharmaceuticals affordability and accessibility, which is projected to support the market growth.
One of the significant factors driving the market growth for radiopharmaceuticals is the rise in the prevalence of chronic diseases such as cancer, cardiovascular disease, and neurology. Radiopharmaceuticals are radioactive drugs that are used to detect and treat cancer cells. They are administered into the body and accumulate in cancerous tissues, allowing for the diagnosis and treatment of the disease.
Around 1.9 million new cancer cases were estimated to have been identified in the U.S. in 2022, according to American cancer Society. In addition, the National Cancer Institute reported that around 50% of all cancer patients are prescribed with radiation therapy at some point during their treatment.
The Japan radiopharmaceuticals market is expected to witness product advancements in the future. With breakthroughs in innovation and also an enhanced focus on medical care framework in the country, companies operating in the market are progressively investing in R&D in order to develop brand-new radiopharmaceuticals with improved efficacy and safety.
Key Benefits For Stakeholders
- Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.
- Analyze the key strategies adopted by major market players in the Japan radiopharmaceuticals market.
- Assess and rank the top factors that are expected to affect the growth of the Japan radiopharmaceuticals market.
- Top player positioning provides a clear understanding of the present position of market players.
- Detailed analysis of the Japan radiopharmaceuticals market segmentation assists to determine prevailing market opportunities.
- Identify key investment pockets for various offerings in the market.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- New Product Development/ Product Matrix of Key Players
- Patient/epidemiology data at country, region, global level
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
- SWOT Analysis
Key Market Segments
By Type
- Diagnostic
- Therapeutic
By End User
- Hospitals and clinics
- Medical Imaging centers
- Others
By Radioisotope
- Fluorine 18
- Iodine I
- Gallium 68
- Others
- Technetium 99m
By Application
- Cancer
- Cardiology
- Others
- Key Market Players
- Daiichi Sankyo Co., Ltd.
- Sumitomo Dainippon Pharma Co., Ltd.
- Fujifilm RI Pharma Co., Ltd.
- Takeda Pharmaceutical Company Limited
- Yakult Honsha Co., Ltd.
- Astellas Pharma Inc.
- Eisai Co., Ltd.
- Kyowa Hakko Kirin Co., Ltd.
- Japan Radioisotope Association
- Japan Pharmaceutical Manufacturers Association
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: JAPAN RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE
CHAPTER 5: JAPAN RADIOPHARMACEUTICALS MARKET, BY APPLICATION
CHAPTER 6: JAPAN RADIOPHARMACEUTICALS MARKET, BY TYPE
CHAPTER 7: JAPAN RADIOPHARMACEUTICALS MARKET, BY END USER
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Companies Mentioned
- Daiichi Sankyo Co., Ltd.
- Sumitomo Dainippon Pharma Co., Ltd.
- Fujifilm RI Pharma Co., Ltd.
- Takeda Pharmaceutical Company Limited
- Yakult Honsha Co., Ltd.
- Astellas Pharma Inc.
- Eisai Co., Ltd.
- Kyowa Hakko Kirin Co., Ltd.
- Japan Radioisotope Association
- Japan Pharmaceutical Manufacturers Association
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
